title: Inducible expression of the long pentraxin PTX3 in the central nervous system.
abstract: PTX3 is a prototypic long pentraxin consisting of a C terminal 203-amino acid pentraxin-like domain coupled with an N-terminal 178-amino acid unrelated portion. PTX3 is induced by primary proinflammatory signals in various cell types, most prominently macrophages and endothelial cells. Other long pentraxins, such as murine or rat neuronal pentraxin 1 (NP1) and human neuronal pentraxin 2 (NPTX2), are expressed in the central nervous system (CNS). The present study was designed to investigate whether PTX3 is expressed in the brain and to define the structures and cells involved. Intracerebroventricular (i.c.v.), but not i.v., injection of LPS induced high levels of PTX3 mRNA in the mouse brain. In contrast NP1 is constitutively expressed in the murine CNS and is not modulated by LPS administration. I.c.v. IL-1beta was also a potent inducer of PTX3 expression in the CNS, whereas TNFalpha was substantially less effective and IL-6 induced a barely detectable signal. Central administration of LPS and IL-1 induced PTX3 also in the periphery (heart), whereas the reverse did not occur. Expression of PTX3 was also observed in the brain of mice infected with Candida albicans (C. albicans) or Cryptococcus neoformans. (C. neoformans). The kinetics of PTX3 gene induction were consistently different between C. albicans- and C. neoformans-infected mice, according to the diverse outcome of the CNS immune reaction. In situ hybridization revealed that i.c.v. injection of LPS induced a strong PTX3 expression in presumptive glial cells, in the white matter (corpus callosum, fimbria) and meningeal pia mater as well as in dentate gyrus hilus and granule cells. No constitutive expression of PTX3 was detected. Central expression of PTX3 may amplify mechanisms of innate resistance and damage in the CNS. The possibility of a direct interaction of PTX3 with neuronal cells, as suggested for NPTX2, remains to be explored.
authors.affiliation: Istituto di Ricerche Farmacologiche 'Mario Negri', Via Eritrea 62, 20157, Milano, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Polentarutti
authors.forename: B
authors.initials: B
authors.lastname: Bottazzi
authors.forename: E
authors.initials: E
authors.lastname: Di Santo
authors.forename: E
authors.initials: E
authors.lastname: Blasi
authors.forename: D
authors.initials: D
authors.lastname: Agnello
authors.forename: P
authors.initials: P
authors.lastname: Ghezzi
authors.forename: M
authors.initials: M
authors.lastname: Introna
authors.forename: T
authors.initials: T
authors.lastname: Bartfai
authors.forename: G
authors.initials: G
authors.lastname: Richards
authors.forename: A
authors.initials: A
authors.lastname: Mantovani
mesh_terms: D000818:Animals; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002097:C-Reactive Protein / Q000235:genetics / Q000378:metabolism*; D002177:Candidiasis / Q000378:metabolism; D003453:Cryptococcosis / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D007276:Injections, Intraventricular; D007375:Interleukin-1 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009206:Myocardium / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D000683:Serum Amyloid P-Component / Q000235:genetics / Q000378:metabolism*; D015533:Transcriptional Activation; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D007375:Interleukin-1; D008070:Lipopolysaccharides; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D011994:Recombinant Proteins; D000683:Serum Amyloid P-Component; D014409:Tumor Necrosis Factor-alpha; D000099153:Pentraxins